Neuprozyme Therapeutics ApS: Financial statements 2024
CVR: 40010106
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -26,502 and a net result of DKK -24,871 compared with DKK -21,211 the year before. Equity in the 2024 report amounted to DKK 107,934. The solvency ratio was 80.9%.
- Gross Profit
- DKK -26,502
- Profit/Loss
- DKK -24,871
- Equity
- DKK 107,934
- Total Assets
- DKK 133,434
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -27K | -25K | 108K | - |
| 2023 | - | -1K | -21K | 133K | - |
| 2022 | - | 576K | 436K | 154K | - |
| 2021 | - | 1M | -289K | -282K | - |
| 2020 | - | -39K | -36K | 7K | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.